Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5577_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •About the Authors
- •Preface
- •Acknowledgements
- •Contents
- •1.1. Singapore as a British Colony
- •1.5.1. Levelling Up the Pharmaceutical Inspection System of Singapore
- •1.5.2. Advantages of PIC/S Membership to Singapore and Other Participating Authorities
- •1.6. Emergence of MNC Pharmaceutical Manufacturing Industry in Singapore
- •1.6.1. Why do MNC Pharmaceutical Manufacturers Set Up Facilities in Singapore?
- •2.2. Geographical Background of ASEAN vis-à-vis Asia and the Rest of the World
- •2.4. Formation of an ASEAN MRA Taskforce on GMP Inspection
- •2.5. Signing of ASEAN Sectoral MRA on GMP Inspection
- •2.6. Formation of ASEAN JSC on GMP Inspection and Establishing Register of ASEAN LIS
- •2.8. Assessment of FDA Philippines by ASEAN PoE
- •2.9. Register of ASEAN Listed Inspection Services (LIS)
- •3.1. Introduction: Urgency of Training ASEAN Inspectors
- •3.3. Collaboration with Korea Ministry of Food and Drug Safety (MFDS)
- •3.4. Collaboration with the Generics and Biosimilars Initiative (GaBI)
- •3.5. Pre-employment Training in Pharmacy and Pharmaceutical Science Schools
- •4.1. Introduction
- •4.2. Historical Context to WHO Reliance Initiative
- •4.3. The First NRAs to Achieve ML4 and WLA Status
- •4.5. Other International Reliance and Harmonization Initiatives
- •4.5.1. Access Consortium
- •4.5.2. Association of Southeast Asian Nations (ASEAN)
- •4.5.3. East African Community (EAC)
- •4.5.4. European Medicines Agency (EMA)
- •4.5.6. International Council for Harmonization (ICH)
- •4.5.6.1. Introduction
- •4.5.6.2. ICH Members and Observers
- •4.5.6.3. Future Direction
- •4.5.7.1. Introduction
- •4.5.7.2. Addressing Common Regulatory Issues
- •4.5.7.3. ICMRA Pilot Program for Collaborative Hybrid Inspection
- •4.5.8. International Pharmaceutical Regulators Program (IPRP)
- •4.5.9. Latin America
- •4.5.10. Pharmaceutical Inspection Co-operation Scheme (PIC/S)
- •4.5.10.1. Introduction
- •4.5.10.2. PIC/S Participating Authorities
- •4.5.11. WHO Collaborative Registration Procedure for Medical Products (CRP)
- •4.5.12.1. Introduction
- •4.5.12.3. WHO Inspection Report
- •4.5.13. ZaZiBoNa
- •4.6. Conclusion
- •5.1. Introduction to GMP
- •5.2. Overview of the PIC/S GMP Standard
- •5.3. How is an On-site GMP Inspection Conducted?
- •5.3.1. Why is the Warehouse Inspected?
- •5.3.3. Why are the Production Areas Inspected?
- •5.3.4. Why are the Packaging Areas Inspected?
- •5.3.5. Why are the QC Laboratories Inspected?
- •5.3.6. Why do GMP Inspectors Visit Other Miscellaneous Areas?
- •5.3.8. Why is there a Need to Conduct Documentation Audit/Review?
- •5.3.8.1. Assessing Product Quality Review
- •5.3.8.3. Assessing Self-Inspection Program
- •5.4. The 20 Annexes of PIC/S GMP Standard
- •5.5. PIC/S Inspection System: A Risk-based Approach
- •5.5.1. Whom can the GMP Inspector Interview?
- •5.5.2.1. Inspector’s Expectations of a Manufacturer
- •5.5.2.2. Manufacturer’s Expectations of an Inspector
- •5.6. Who Inspects the Inspectors?
- •6.1. Historical Development of Pharmaceutical Quality
- •6.2. What is a High-Quality Medicinal Product?
- •6.3. Purity of a Medicinal Product: Elimination of Impurities and Contaminants
- •6.3.1. What is a Contaminated Medicinal Product?
- •6.3.2. Why is There a Need to Control Impurities?
- •6.3.2.1. Types of Impurities from APIs
- •6.3.2.2. Types of Impurities from Container-Closure System
- •6.3.3. Control of Intrinsic Contaminants
- •6.3.4. Control of Extrinsic Contaminants
- •6.3.5. General Assessment of Cross-Contamination Risks
- •6.4. Stability and Shelf-Life Testing of a Medicinal Product
- •6.4.1. Why is Proper Storage, Distribution and Handling of a Medicinal Product Important?
- •6.6. Summary of High-Quality Medicinal Products
- •7.1. Introduction to Stability and Quality
- •7.3.1. Why is Proper Storage Important?
- •7.3.2. Why is Proper Transportation of a Medicinal Product Important?
- •7.3.3. Why is Proper Handling of a Medicinal Product during Use Important?
- •7.4.1. Number and Size of Batches
- •7.4.2. Testing Frequency
- •7.4.3. Storage Conditions
- •7.4.4. Test Methods
- •7.4.5. Container-Closure Systems
- •7.5. Stability Study Schedule and Report
- •7.6. Temperature Excursions and Product Stability
- •7.8. Cold Chain Products and Temperature Excursions
- •7.11. Conclusion
- •8.1. Christopher Columbus versus the Vikings
- •8.4. Pharmaceutical Data Integrity and ALCOA
- •8.5. Article(s) on Pharmaceutical Data Integrity
- •Introduction
- •Current trends
- •Reasons for Data Integrity violations (inadvertent and intentional)
- •Assuring and promoting Data Integrity via legislation and guidance documents
- •Legislation
- •Guidance documents
- •Proposed Solutions to Better Promote and Assure Data Integrity
- •Culture of integrity
- •Database management systems
- •Robust quality agreements
- •Collaboration between countries
- •Computerized systems validation
- •List of abbreviations
- •Conclusion
- •Authors
- •References
- •9.1. Pharmaceuticals versus Biopharmaceuticals
- •9.2. Transcription and Translation: Central Dogma of Genetics
- •9.3. Biotechnology-derived Medicinal Products: Microbial versus Mammalian Substrates
- •9.4. Manufacture of Biotechnology-derived Medicinal Products: Key Processes
- •Introduction
- •Manufacture of biopharmaceuticals — an overview
- •Procurement and testing of biological starting materials
- •Generation and characterization of cell banks/seed lots
- •Cell culturing
- •Challenges concerning manufacture of biopharmaceuticals
- •Extensive process and product understanding required
- •Inherent variability of host cells
- •Downstream processing remains a key bottleneck
- •Review of current GMP frameworks for biopharmaceuticals
- •Challenges in the regulation of biopharmaceuticals
- •Resource-intensive evaluation of biosimilarity
- •Growing number of data integrity lapses
- •Proposed solutions to challenges of biopharmaceuticals
- •Optimizing biopharmaceutical manufacturing with Industry 4.0
- •Enhancing data integrity with a culture of quality (quality culture)
- •Conclusion
- •List of abbreviations
- •Authors
- •References
- •10.1. Introduction
- •10.2. Advantages of Nanomedicines
- •10.3. Types of Nanomedicines
- •10.3.1. Nanocarrier Systems
- •10.3.2. Nanosuspensions
- •10.4. Future of Nanomedicines
- •10.5. GMP Requirements Governing Nanomedicines and Challenges
- •10.5.1. Lack of Trained Personnel to Operate Manufacturing Processes
- •10.5.2. Lack of Safety Protocol for Manufacturing Personnel
- •10.5.3. Challenges in Controlling for Nanoparticle Contamination
- •10.6. Conclusion
- •11. Novel and Traditional Vaccines
- •11.1. Historical Development and Evolution of Traditional and Novel Vaccines
- •11.2. Traditional Vaccines Versus Novel Vaccines
- •Introduction
- •Traditional vaccines
- •Novel vaccines
- •Vaccine manufacture
- •Vaccine storage, transport and distribution
- •Regulatory controls
- •Challenges, safety and quality issues and possible solutions
- •Conclusion
- •Authors
- •References
- •12.1. Cells and Tissues
- •12.2. Gene Therapy Products
- •12.3. Published Article on CTGTPs
- •Introduction
- •CTGTPs and their principles of action
- •Manufacturing of CTGTPs
- •Premises and equipment
- •Materials and processing
- •Starting material
- •Quality control
- •Cryopreservation
- •Human resource and accreditation
- •Potential solutions to the challenges encountered in manufacturing
- •Outsourcing
- •Technology
- •Control of CTGTPs
- •Current regulatory framework
- •Risk-based approach
- •Conclusion
- •Authors
- •References
- •13. Hand Sanitizers
- •13.1. What are Hand Sanitizers?
- •13.4. Published Article and Commentary on Hand Sanitizers
- •Introduction
- •The microbiology of bacteria, fungi and viruses
- •Antimicrobial compounds and their applications in hand sanitizers
- •FDA policy for testing of alcohol and USP limits for methanol
- •Common myths about hand sanitizers
- •A lack of regulatory framework
- •Proposed solutions
- •Tightening the regulatory framework
- •Training pharmacists on hand sanitizer vigilance
- •Public Education
- •Conclusion
- •Authors
- •References
- •14. Pharmaceutical Dosage Forms
- •14.1. Introduction
- •14.2. What Are Pharmaceutical Dosage Forms?
- •14.4.1. Routes of Administration
- •14.4.1.1. Oral Dosage Forms — Solids
- •14.4.1.2. Oral Dosage Forms — Liquids
- •14.4.1.3. Topical Dosage Forms
- •14.4.1.5. Inhaled Dosage Forms
- •14.4.1.6. Ophthalmic Dosage Forms
- •14.4.1.7. Nasal Dosage Forms
- •14.4.1.8. Otic Dosage Forms
- •14.4.1.9. Rectal Dosage Forms
- •14.4.1.10. Vaginal Dosage Forms
- •14.4.1.11. Transdermal Patch
- •14.4.2. Physical Forms
- •14.4.2.1. Solid Dosage Forms
- •14.4.2.2. Liquid Dosage Forms
- •14.4.2.3. Semi-solid Dosage Forms
- •14.4.2.4. Gaseous or Aerosol Dosage Forms
- •14.5. Manufacture and Important Characteristics of Common Pharmaceutical Dosage Forms
- •14.5.1. Tablets
- •14.5.2. Capsules
- •14.5.3. Solutions
- •14.5.4. Suspensions
- •14.5.5. Emulsions
- •14.5.6. Creams
- •14.5.7. Ointments
- •14.5.8. Metered Dose Inhalers
- •14.6. Overall Summary of the Manufacture of a Pharmaceutical Dosage Form
- •15.1. Introduction




Published by
World Scientic Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
USA oce: 27 Warren Street, Suite 401-402, Hackensack, NJ 07601
UK oce: 57 Shelton Street, Covent Garden, London WC2H 9HE
Library of Congress Cataloging-in-Publication Data
Names: Chan, Lai Wah, author. | Sia, Chong Hock, author.
Title: Manufacture and supply, science and regulation towards high-quality medicinal products /
Lai Wah Chan, Chong Hock Sia.
Description: New Jersey : World Scientic, [2025] | Includes bibliographical references and index.
Identiers: LCCN 2024025058 | ISBN 9789811295492 (hardcover) |
ISBN 9789811295508 (ebook for institutions) | ISBN 9789811295515 (ebook for individuals)
Subjects: LCSH: Pharmaceutical technology--Standards. | Pharmaceutical industry--Standards.
Classication: LCC RS192 .C52155 2025 | DDC 338.4/76151--dc23/eng/20240820
LC record available at https://lccn.loc.gov/2024025058
British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library.
Copyright © 2025 by World Scientic Publishing Co. Pte. Ltd.
For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance
Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case permission to photocopy
is not required from the publisher.
For any available supplementary material, please visit
https://www.worldscientic.com/worldscibooks/10.1142/13909#t=suppl
Desk Editor: Shaun Tan Yi Jie
Typeset by Stallion Press
Email: enquiries@stallionpress.com
Printed in Singapore

About the Authors
v
Dr Chan Lai Wah is an Associate Professor in
Pharmaceutics at the Department of Pharmacy
and Pharmaceutical Sciences of the National
University of Singapore (NUS), where she has
lectured for more than 30 years and won many
awards for excellence in teaching. In particular,
she has been placed on the NUS Faculty Honor
Roll for a record three times in 2005, 2009 and
2015 for continuous teaching excellence. She is also the co-founder
of GEA-NUS Pharmaceutical Processing Research Laboratory,
which serves as an international platform for promoting research
and manpower training in process technology. Her research interests include pharmaceutical formulation and processing, pharmaceutical microbiology, and the quality and safety issues of medicinal
products. To date, she has supervised and successfully graduated 34 PhD and 9 MSc students by research. In addition, she has

vi
Manufacture and Supply, Science and Reg ulation Towards High-Qua lity Medicinal Products
co-authored about
180 scientific papers
in peer-reviewed
journals besides
numerous conference papers. She
has also served as a
technical expert for
the Singapore Ac cre ditation Council,
scientific reviewer
for local and overseas research grants,
thesis examiner for local and overseas universities as well as reviewer
for international scientific journals.
In addition to her research and teaching excellence, Professor Chan
has devoted much of her time to service and leadership. She was SubDean of the Faculty of Science from July 2000 to April 2002. Since
2000, she has served in many programs and committees, including
Chair of the Science Research Program, NUS Science Mentorship
Program and Faculty Alumni Day Committee. For many years, she
had been the Chair of NUS Pharmacy Graduate Program Committee, Chair of the Pharmacy Department Teaching Excellence Committee, Member of Faculty of Science Teaching Excellence Committee, as well as Member of the Selection Panel for NUS Scholarships.
She was also Chair of the Organizing Committee for the 14th International Microencapsulation Symposium, as well as organizing
committee member for numerous regional and international pharmaceutical technology conferences and workshops. More recently
from 2021 to 2023, she was appointed to the NUS Senate Delegacy.

About the Authors
Mr Sia Chong Hock has been the Director of
Quality Assurance and Senior Consultant of
Audit and Licensing at the Singapore Health
Sciences Authority (HSA) since 2015 to date,
where he was previously the Director of the
Audit and Licensing Division in the period
2008–2015. From 1995 to 2022, he was also an
Adjunct Associate Professor at the Department
of Pharmacy and Pharmaceutical Sciences of the National University of Singapore (NUS). He had been a member of the Singapore
Pharmacy Council and its predecessor Singapore Pharmacy Board
from 2002 to 2018, including being the Chair of its Complaints
Panel. He holds a Bachelor’s degree in Pharmacy from NUS, as well
as a Master’s degree in Healthcare Management (with Distinction)
from the University of Wales, UK.
vii
Mr Sia has played a monumental role in, and won many awards for,
shaping Singapore to be a world leader in pharmaceutical regulation.
He took up the challenge to set up the GMP Audit Unit and led Singapore to become the first Asian member of the international Phar maceutical Inspection Co-operation
Scheme (PIC/S) in
2000, and was subsequently appointed
Chair of the ASEAN
MRA Task Force
and Joint Sectoral
Committee on
GMP Inspection
from 2005 to 2020.

viii
Manufacture and Supply, Science and Reg ulation Towards High-Qua lity Medicinal Products
In 2013, he was conferred
the Industry Pharmacist
of the Year Award by the
Pharmaceutical Society
of Singapore, and in 2016,
he was honored with the
International Pharmaceutical Society of Pharmaceutical Engineering (ISPE) Singapore Aliate Lifetime
Achievement Award for his
contributions to the field of
Pharmaceutical Regulatory Practices in Singapore and the ASEAN
region. More recently, he was a recipient of the PS(Health) Award
2023 for his key role as a core team member responsible for HSA
being the first National Regulatory Authority (NRA) in the world
to achieve Maturity Level 4 under the World Health Organization
Global Benchmarking Tools (WHO GBT) assessment. This WHO
GBT certification confirms HSA as an NRA that is operating at an
advanced level of regulation in medicinal products and vaccines. On
the academic front, he contributes review articles to international
scientific journals, covering the regulation of pharmaceuticals and
biopharmaceuticals. In 2016 and 2019, two of his articles won the
ISPE Roger Sherwood Article of the Year Award.

Preface
ix
The COVID-19 pandemic, ocially declared by the World Health
Organization (WHO) in March 2020, was a black swan event. The
rapid spread of COVID-19 across international borders and its
impact on the world were unexpected and unprecedented. A record
number of people lost their lives, and there were numerous sad, sorrowful and heartbreaking stories. All domestic and international
business activities grounded to a halt, and most people stayed at
home or worked remotely. At the height of the pandemic, there
was a global surge of interest in COVID-19 vaccines, anti-viral and
anti-bacterial drugs, hand sanitizers, disinfectants, face masks and
other medicinal and healthcare products. When it became apparent that the COV ID-19 pandemic was going to be protracted, we
(the authors) began looking for silver linings amidst the dark clouds
of the pandemic. We began to look for educational materials on
vaccines, pharmaceuticals and biopharmaceuticals, and discovered
that we collectively possess a “treasure trove” of these materials.

x
Manufacture and Supply, Science and Reg ulation Towards High-Qua lity Medicinal Products
Our prized possessions range from our lecture notes to undergraduate and graduate students, to published scientific papers and conference presentations on these topics, as well as our own personal
experiences. At that juncture, we decided that these sets of knowledge and materials should be systematically assembled into a book
and be shared with all interested parties. Thus, it can be said that
the seeds for this work were sown sometime during the peak of the
COV ID-19 pandemic.
In this book, readers will get to understand quality and safety issues
relating to a broad spectrum of medicinal products, which are also
referred to as medical products, medicines, drug products, therapeutic products or generally as healthcare products by dierent
national jurisdictions, regional and international organizations.
Depending on the discussion topic, these terms may be used interchangeably to align with the terminology most commonly used
in the countries or geographical regions concerned. The products
covered herein range from traditional and herbal medicinal products, health supplements, to pharmaceuticals and biopharmaceuticals, including recombinant proteins, monoclonal antibodies, novel
and traditional vaccines, as well as cells, tissues and gene therapy
products. The upstream manufacture and assurance of quality and
supply chain integrity for active pharmaceutical ingredients and
excipients, narcotic drugs and psychotropic substances, have been
given their due attention too. Quality and safety issues arising from
product contamination and adulteration, as well as falsified and
counterfeit medicines have also been highlighted, together with
their trends and proposed solutions to combat these sub-standard
and spurious medicines. Concurrently, the book examines the risks
and opportunities, as well as the challenges and benefits, faced by
pharmaceutical manufacturers, regulatory authorities and the
Соседние файлы в папке Библиотека им академика М.И. Перельмана
